Solid Biosciences (NASDAQ:SLDB - Get Free Report) issued its earnings results on Thursday. The company reported ($0.89) earnings per share for the quarter, missing analysts' consensus estimates of ($0.79) by ($0.10), Zacks reports.
Solid Biosciences Trading Down 6.1 %
Shares of NASDAQ SLDB traded down $0.33 during midday trading on Monday, hitting $5.09. The company's stock had a trading volume of 1,744,451 shares, compared to its average volume of 2,905,388. The business's 50 day moving average is $4.07 and its two-hundred day moving average is $5.53. Solid Biosciences has a 12-month low of $2.88 and a 12-month high of $15.05. The firm has a market cap of $388.46 million, a P/E ratio of -1.67 and a beta of 1.98.
Wall Street Analyst Weigh In
SLDB has been the subject of several research reports. HC Wainwright increased their price objective on shares of Solid Biosciences from $16.00 to $20.00 and gave the company a "buy" rating in a report on Monday. JMP Securities began coverage on Solid Biosciences in a report on Tuesday, December 10th. They set an "outperform" rating and a $15.00 price target for the company. Chardan Capital reaffirmed a "buy" rating and set a $16.00 price objective on shares of Solid Biosciences in a report on Friday. Wedbush began coverage on shares of Solid Biosciences in a report on Friday, December 13th. They issued an "outperform" rating and a $16.00 target price for the company. Finally, Truist Financial initiated coverage on shares of Solid Biosciences in a research note on Wednesday, January 8th. They set a "buy" rating and a $16.00 price target on the stock. Nine investment analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $15.80.
Get Our Latest Analysis on SLDB
Solid Biosciences Company Profile
(
Get Free Report)
Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.
Further Reading
Before you consider Solid Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solid Biosciences wasn't on the list.
While Solid Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
